These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 20640529)

  • 1. Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity.
    Puttananjaiah MK; Dhale MA; Gaonkar V; Keni S
    Appl Biochem Biotechnol; 2011 Jan; 163(2):215-22. PubMed ID: 20640529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
    Haendeler J; Hoffmann J; Zeiher AM; Dimmeler S
    Circulation; 2004 Aug; 110(7):856-61. PubMed ID: 15289372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
    Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
    Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
    Cirillo P; Pacileo M; De Rosa S; Calabrò P; Gargiulo A; Angri V; Prevete N; Fiorentino I; Ucci G; Sasso L; Petrillo G; Musto D'Amore S; Chiariello M
    J Vasc Res; 2007; 44(6):460-70. PubMed ID: 17657162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin.
    Ajith TA; Riji T; Anu V
    Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):625-9. PubMed ID: 18177480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro screening for β-hydroxy-β-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
    Iqbal D; Khan MS; Khan A; Khan MS; Ahmad S; Srivastava AK; Bagga P
    Biomed Res Int; 2014; 2014():762620. PubMed ID: 24883325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
    McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
    Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
    Kreuzer J; Watson L; Herdegen T; Loebe M; Wende P; Kübler K
    Eur J Med Res; 1999 Apr; 4(4):135-43. PubMed ID: 10205288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
    Ito MK; Talbert RL; Tsimikas S
    Pharmacotherapy; 2006 Jul; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural mechanism for statin inhibition of HMG-CoA reductase.
    Istvan ES; Deisenhofer J
    Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of essential oils of dietary wormwood (Artemisia princeps), with and without added vitamin E, on oxidative stress and some genes involved in cholesterol metabolism.
    Chung MJ; Kang AY; Park SO; Park KW; Jun HJ; Lee SJ
    Food Chem Toxicol; 2007 Aug; 45(8):1400-9. PubMed ID: 17368686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin on trioleylglycerol hydrolysis and transacylation with cholesterol in serum of outpatients with coronary heart disease.
    Pioruńska-Stolzmann M; Pioruńska-Mikolajczak A; Mikolajczyk Z
    Drugs Exp Clin Res; 2003; 29(1):37-43. PubMed ID: 12866362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.